UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 177

Sortiert nach

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Nature (London), 2014-11, Vol.515 (7528), p.558-562

2014

Link zum Volltext

Verfügbarkeit prüfen

Liposome-encapsulated curcumin : In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

Cancer, 2005-09, Vol.104 (6), p.1322-1331

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors

Cancer, 2023-06, Vol.129 (12), p.1919-1929

2023

Link zum Volltext

Verfügbarkeit prüfen

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.357-359

2015

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Link zum Volltext

Verfügbarkeit prüfen

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

The lancet oncology, 2023-05, Vol.24 (5), p.496-508

2023

Link zum Volltext

Verfügbarkeit prüfen

Liposome‐encapsulated curcumin

Cancer, 2005-09, Vol.104 (6), p.1322-1331

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600 -mutated solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3098-3098

2023

Link zum Volltext

Verfügbarkeit prüfen

EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3647-TPS3647

2020

Link zum Volltext

Verfügbarkeit prüfen

Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.49-49

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3523-3523

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I results from a phase 1/2 multi-center study of nab -sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16050-e16050

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3144-TPS3144

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT125-CT125

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT165-CT165

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer management and research, 2017-01, Vol.9, p.141-148

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-world analysis of treatment patterns examining nab -Paclitaxel plus Gemcitabine ( nab -P+G) versus FOLFIRINOX (FFX) in first-line (1L) treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18130-e18130

2016

Link zum Volltext

Verfügbarkeit prüfen

Real-world analysis of treatment patterns examining nab -Paclitaxel plus gemcitabine ( nab -P+G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18100-e18100

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5550-5550

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5509-5509

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness of early-line nab -paclitaxel ( nab -P) versus eribulin in patients (pts) with metastatic breast cancer (MBC): A U.S. real-world analysis

Journal of clinical oncology, 2016-03, Vol.34 (7_suppl), p.293-293

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Englisch
(177)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(59)
Humans
(54)
Oncology
(45)
Male
(38)
Female
(35)
Middle Aged
(35)
Aged
(28)
Adult
(26)
Tumors
(20)
Aged, 80 And Over
(15)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Neoplasms - Drug Therapy
(12)
Patients
(11)
Chemotherapy
(10)
Treatment Outcome
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Cancer
(8)
Cancer Therapies
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Liposome-encapsulated curcumin : In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Liposome‐encapsulated curcumin

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600 -mutated solid tumors

EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors

Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma

Phase I results from a phase 1/2 multi-center study of nab -sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress)

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Real-world analysis of treatment patterns examining nab -Paclitaxel plus Gemcitabine ( nab -P+G) versus FOLFIRINOX (FFX) in first-line (1L) treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Real-world analysis of treatment patterns examining nab -Paclitaxel plus gemcitabine ( nab -P+G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC)

Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies

Comparative effectiveness of early-line nab -paclitaxel ( nab -P) versus eribulin in patients (pts) with metastatic breast cancer (MBC): A U.S. real-world analysis

Suchergebnisse filtern